Xencor在AACR-NCI-EOTTC上展示了正在进行的Xmab 819（ENPP 3 X CD 3 T细胞接合双特异性抗体）在晚期ccCC患者中进行的I期剂量逐步增加研究的初步结果

-- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC --

-- 25% overall response rate (ORR) observed within the target dose range --

-- First dose-expansion cohort has been selected; dose escalation continues to identify dose for second expansion cohort --

-- Management hosting webcast and conference call today at 1:30 p.m. ET / 10:30 a.m. PT --

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced initial results from the ongoing Phase 1 dose-escalation study of XmAb819, a ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC). The results were presented in a poster at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts.